Gene · 10038
PARP2: poly(ADP-ribose) polymerase 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PARP2: poly(ADP-ribose) polymerase 2. Genes, record 10038. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10038
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UGN5 | Poly [ADP-ribose] polymerase 2 | 583 | 30 | Ensembl, GeneID, HGNC |
Source UniProt
Patents30
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4464338 A2 | 2024-11-20 | 149 | Q9UGN5 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 7751 | Q9UGN5 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 176 | Q9UGN5 | Espacenet |
| US 11680268 B2 | 2023-06-20 | 149 | Q9UGN5 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64495 | Q9UGN5 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167466 | Q9UGN5 | Espacenet |
| US 11293927 B2 | 2022-04-05 | 14 | Q9UGN5 | Espacenet |
| US 10695341 B2 | 2020-06-30 | 227 | Q9UGN5 | Espacenet |
| WO 2020058277 A1 | 2020-03-26 | 6 | Q9UGN5 | Espacenet |
| JP 2020508335 A | 2020-03-19 | 176 | Q9UGN5 | Espacenet |
1 to 10 of 30
See all 30 patentsDrugs12
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| 2X-121 | CHEMBL3644587 | Poly [ADP-ribose] polymerase 2 inhibitor | INHIBITOR | ChEMBL |
| E-7016 | CHEMBL3527000 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| NIRAPARIB | CHEMBL1094636 | Poly [ADP-ribose] polymerase 2 inhibitor | INHIBITOR | ChEMBL |
| NIRAPARIB TOSYLATE MONOHYDRATE | CHEMBL3989922 | Poly [ADP-ribose] polymerase 2 inhibitor | INHIBITOR | ChEMBL |
| OLAPARIB | CHEMBL521686 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| PAMIPARIB | CHEMBL4112930 | Poly [ADP-ribose] polymerase 2 inhibitor | INHIBITOR | ChEMBL |
| RUCAPARIB | CHEMBL1173055 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| RUCAPARIB CAMSYLATE | CHEMBL3833368 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| SENAPARIB | CHEMBL4802152 | Poly [ADP-ribose] polymerase 2 inhibitor | INHIBITOR | ChEMBL |
| TALAZOPARIB | CHEMBL3137320 | Poly [ADP-ribose] polymerase 2 inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 12
See all 12 drugsTrials819
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07586449 | SENAPARIB | ClinicalTrials.gov | ||
| NCT07486687 | OLAPARIB | PHASE3 | ClinicalTrials.gov | |
| NCT07460180 | OLAPARIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07407452 | OLAPARIB | PHASE2 | ClinicalTrials.gov | |
| NCT07371104 | OLAPARIB | PHASE1 | ClinicalTrials.gov | |
| NCT07187674 | OLAPARIB | ClinicalTrials.gov | ||
| NCT07151911 | OLAPARIB | ClinicalTrials.gov | ||
| NCT07120451 | SENAPARIB | PHASE2 | ClinicalTrials.gov | |
| NCT07113964 | OLAPARIB | PHASE2 | ClinicalTrials.gov | |
| NCT07090369 | OLAPARIB | PHASE1 | ClinicalTrials.gov |
1 to 10 of 819
See all 819 trialsNIH grants1,388
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PARP2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 27 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 19 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 18 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 18 | 2025 |
| R01DK069710 | The Role of Nuclear PARPs in Signal-Regulated Transcription | 15 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 11 | 2025 |
| ZIABC006150 | DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs | 11 | 2025 |
| ZIABC011078 | Phase 0-1 Clinical Trials | 11 | 2025 |
| R01CA218255 | Structure and Mechanism of Chromatin-Bound PARP1 | 9 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 8 | 2025 |
1 to 10 of 1,388Source NIH's project files
See all 1,388 nih grantsPapers2,674
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Screening of Programmed Cell Death-Related Biomarkers and Exploration of Mechanisms in Zhenwu Decoction for Treating Chronic Kidney Disease. | Comb Chem High Throughput Screen | 2026 | 42817110 | PubTator, text mining | PubMed |
| ZIPPing the gaps: A new class of zinc finger proteins orchestrates the DNA damage response. | DNA Repair (Amst) | 2026 | 42762747 | PubTator, text mining | PubMed |
| Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors. | J Med Chem | 2026 | 42720455 | PubTator, text mining | PubMed |
| Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. | PLoS One | 2026 | 42685115 | PubTator, text mining | PubMed |
| Heterocyclic Scaffolds in PARP-1 Inhibition: An Emerging Strategy for Targeted Anticancer Therapy. | Mini Rev Med Chem | 2026 | 42634307 | PubTator, text mining | PubMed |
| From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors. | Front Oncol | 2026 | 42568603 | PubTator, text mining | PubMed |
| Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K/AKT/mTOR signaling pathway. | Bioorg Med Chem | 2026 | 42531674 | PubTator, text mining | PubMed |
| ROS-Induced DNA Damage Enhances Sensitivity to PARP Inhibition in HSC3 and SCC25 Head and Neck Squamous Cell Carcinoma Cell Lines. | Curr Issues Mol Biol | 2026 | 42510932 | PubTator, text mining | PubMed |
| Allosteric activation of PARP2 self-PARylation by SUMO constrains DNA-break-dependent catalytic functions. | FEBS J | 2026 | 42479900 | PubTator, text mining | PubMed |
| Integrating single-cell sQTL mapping with deep-learning splicing prediction identifies causal variants under influenza infection. | Genome Biol | 2026 | 42471654 | PubTator, text mining | PubMed |
1 to 10 of 2,674
See all 2,674 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10038
GET https://conductscience.org/api/genes/v1/10038/patents?page=2